Drug Trial Radar · NCT06185985
Open-label Safety and Efficacy of SPN-812 (Viloxazine Extended-release Capsule) in Adults With ADHD and Mood Symptoms
Last checked: Nov 20, 2026Latest source record: Mar 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
161
Actual
Start
Mar 25, 2024
Primary completion
Dec 3, 2024
Study completion Dec 11, 2024
Sponsor
- Lead sponsor
- Supernus Pharmaceuticals, Inc.Industry
- Sponsor type
- Industry
- First posted
- Dec 29, 2023
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
Open label, flexible dose, decentralized clinical trial evaluating the efficacy and safety of SPN-812 in adults with ADHD and mood symptoms.
Conditions
- Attention-Deficit/Hyperactivity Disorder
Interventions
SPN-812Drug
Open-label
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change From Baseline in the Adult ADHD Investigator Symptom Rating Scale (AISRS) Total Score by Visit.Time frame: Baseline and Week 4, 9, and 14
Locations
1 site in 1 country. Site status is shown where the registry gives one.
ObvioHealth
New York, New York
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.